Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 180,958,192
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.86
  • Price/Sales 4.54
  • Price/Cash Flow 11.39
  • Price/Book 4.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.69 +5.54%
on 06/16/17
66.39 -0.35%
on 06/23/17
+1.61 (+2.49%)
since 05/23/17
3-Month
61.87 +6.93%
on 04/21/17
66.39 -0.35%
on 06/23/17
+2.88 (+4.55%)
since 03/23/17
52-Week
55.10 +20.07%
on 06/27/16
66.80 -0.96%
on 03/01/17
+8.48 (+14.70%)
since 06/23/16

Most Recent Stories

More News
Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

DARMSTADT, Germany, June 24, 2017 /PRNewswire/ --

MRK : 66.16 (+0.21%)
Acelity Strengthens Global Commercial Leadership; Names Ramesh Subrahmanian President for International Region

Acelity L.P. Inc., a leading global advanced wound care company, today announced Ramesh Subrahmanian will join the company as President for the International region and member of the senior...

SYK : 141.12 (-0.07%)
MRK : 66.16 (+0.21%)
Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis

DARMSTADT, Germany, June 23, 2017 /PRNewswire/ --

MRK : 66.16 (+0.21%)
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
NVS : 86.34 (unch)
SHPG : 172.98 (-1.11%)
RHHBY : 32.7600 (+1.42%)
BMY : 56.64 (-1.20%)
NEOS : 7.25 (-2.03%)
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in...

CNCR : 23.68 (+1.11%)
BLUE : 112.00 (-5.49%)
MRK : 66.16 (+0.21%)
INCY : 136.28 (+0.48%)
KITE : 100.66 (+7.10%)
PFE : 34.17 (+0.32%)
Why You Should Add Novo Nordisk Stock to Your Portfolio

Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
SNY : 49.33 (-0.56%)
Merck's Keytruda on a Roll: Can it Retain the Momentum?

As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma...

MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
AMGN : 172.50 (-0.76%)
PFE : 34.17 (+0.32%)
Glaxo's (GSK) Shingles Candidate Phase III Data Positive

GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

VVUS : 1.22 (+5.17%)
MRK : 66.16 (+0.21%)
TEVA : 32.61 (+0.28%)
GSK : 44.29 (+0.29%)
Merck and Premier Inc. Expand Collaboration to Address Chronic Care and Vaccination Rates

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have expanded their efforts to co-develop...

MRK : 66.16 (+0.21%)
PINC : 35.35 (+0.48%)
Ligand Gets Milestone Payment on Partner Drug FDA Approval

Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the...

LGND : 123.87 (+0.60%)
MRK : 66.16 (+0.21%)
NVS : 86.34 (unch)
AMGN : 172.50 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 66.68
1st Resistance Point 66.42
Last Price 66.16
1st Support Level 65.87
2nd Support Level 65.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.